Deep brain stimulation of the subcallosal cingulate for medication‐resistant type I bipolar depression: case report

C. Torres,E. Ezquiaga,M. Navas,R. Sola

DOI: https://doi.org/10.1111/bdi.12102

2013-09-01

Bipolar Disorders

Abstract:Patients with unipolar depression have been reported as having derived benefit from deep brain stimulation (DBS) of the subcallosal cingulate (1–8). Experience with DBS for bipolar depression is scarce, and limited to patients with type II bipolar depression (1–8). We present the first case of type I bipolar disorder successfully treated with DBS of this area. The patient was a 78-year-old woman diagnosed with DSM-IV recurrent and severe type I bipolar depression, without other comorbid disorders. She was initially diagnosed with unipolar depression in 1984, but she gradually developed clinically significant episodes of mania for which lithium was introduced in 1995 with an initial irregular compliance. Since that time, she had experienced multiple relapses of depression and manic episodes, requiring frequent admissions to the acute psychiatric unit. Response to treatment with various stabilizers (constant lithium, valproate, and lamotrigine), antipsychotics (olanzapine, quetiapine, pimozide, and haloperidol), and antidepressants (dual, selective serotonin reuptake inhibitors), alone and in combinations, was poor. In 2009, she developed a severe depressive episode that persisted for two years, with mood-congruent psychotic symptoms (Cotard syndrome), despite good adherence to treatment for several years previously. Other drugs such as quetiapine, pimozide, escitalopram, or bupropion were also administered at effective doses. Several admissions to the hospital for electroconvulsive therapy (a total of 42 sessions) were required, with limited clinical response. Therefore, she was considered for DBS. Our local ethics committee approved the surgical treatment and informed consent was obtained from the patient and her family. The patient underwent brain magnetic resonance imaging (MRI) and a complete neuropsychological evaluation, which did not show any significant abnormalities (her scores at Mini-Mental State Examination were 29/30). Preoperatively, she was taking quetiapine 300 mg/day, pimozide 2 mg/day, escitalopram 40 mg/day, bupropion 300 mg/day, and lithium 600 mg/day (lithemia levels in range). The implantation of the DBS system was performed according to standard techniques (2, 6, 9). A Leksell G-frame was applied to the patient’s head with local anesthesia and a computerized tomography (CT) scan was executed and merged with a previously performed T1 3D MRI, and rebuilt in axial, coronal, and sagittal planes. The target location was selected according to Hamani et al. (1) (see Fig. 1). Libra electrodes (St Jude Medical, Plano, TX, USA), consisting of a 3-mm distal contact and three 1-mm proximal contacts spaced 0.5 mm apart, were implanted at the planned targets and connected to bilateral Libra internal pulse generators (St Jude Medical). During the immediate postoperative period, the patient had a tonic–clonic seizure, which spontaneously subsided. A CT was quickly performed, which ruled out any intracranial hemorrhage. Three days following the procedure, a postoperative MRI was obtained. Despite the MRI quality being poor due to movement artefacts, it was sufficient to visualize the contact location. On the first postoperative day, the patient and caregivers reported an improvement in her depression symptoms, which lasted for three days, after which she returned to her baseline. Stimulation was commenced 15 days after the operation, at the initial parameters proposed by Holtzeimer et al. (2): 130 Hz, 91 ls, and 6 mA. Contacts were 3 – C+ on the right side and 1 – C+ on the left side, according to their position in the postoperative MRI, which showed that the right electrode was situated deeper than initially planned. From the first month of stimulation, the patient presented